{
    "organizations": [],
    "uuid": "f82f236b30a1040b9019f56e32e18543460ec283",
    "author": "",
    "url": "https://www.reuters.com/article/brief-pharmabcine-enters-in-collaboratio/brief-pharmabcine-enters-in-collaboration-with-msd-idUSFWN1PR0UM",
    "ord_in_thread": 0,
    "title": "BRIEF-PharmAbcine Enters in Collaboration With MSD",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 1 (Reuters) - Merck & Co Inc:\n* PHARMABCINE ENTERS COLLABORATION WITH MSD FOCUSED ON CLINICAL EVALUATION OF TTAC-0001 IN COMBINATION WITH KEYTRUDAÂ® (PEMBROLIZUMAB) IN RECURRENT GLIOBLASTOMA AND BREAST CANCER\n* PHARMABCINE SAYS WILL CONDUCT INTERNATIONAL PHASE I/II STUDIES TO EVALUATE POTENTIAL CLINICAL SYNERGY OF COMBINING TTAC-0001 WITH KEYTRUDA\n* PHARMABCINE INC SAYS HAS ENTERED INTO A COLLABORATIVE AGREEMENT WITH MSD Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-01T14:10:00.000+02:00",
    "crawled": "2018-02-01T14:29:24.023+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "merck",
        "co",
        "inc",
        "pharmabcine",
        "enters",
        "collaboration",
        "msd",
        "focused",
        "clinical",
        "evaluation",
        "combination",
        "pembrolizumab",
        "recurrent",
        "glioblastoma",
        "breast",
        "cancer",
        "pharmabcine",
        "say",
        "conduct",
        "international",
        "phase",
        "study",
        "evaluate",
        "potential",
        "clinical",
        "synergy",
        "combining",
        "keytruda",
        "pharmabcine",
        "inc",
        "say",
        "entered",
        "collaborative",
        "agreement",
        "msd",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}